Data on the clinical course of lupus anticoagulant (LA) positive individuals with or without thrombotic manifestations or pregnancy complications are limited. To investigate mortality rates and factors that might influence mortality, we conducted a prospective observational study of LA positive individuals. In total, 151 patients (82% female) were followed for median of 8.2 years, of whom 30 patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events) and 20 patients (13%) died. In univariable analysis new onset of thrombosis (HR=8.76, 95%CI 3.46-22.16) was associated with adverse survival. Thrombosis remained a strong adverse prognostic factor after multivariable adjustment for age and hypertension (HR=5.95, 95%CI 2.43-14.95). Concomitant autoimmune diseases, anticoagulant treatment at baseline or positivity for anticardiolipin-or anti-ß2-glycoprotein I antibodies were not associated with mortality. In a relative survival analysis, our cohort of LA positives showed a persistently worse survival in comparison to an age-, sex-, and studyinclusion-year-matched Austrian reference population. The cumulative relative survival was 95.0% (95%CI 88.5-98.8) after 5 and 87.7% (95%CI 76.3-95.6) after 10 years.
Introduction
Antiphospholipid antibodies (aPLA), such as lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and antibodies against ß2-glycoprotein I (anti-ß2GPI) comprise a group of heterogeneous circulating autoantibodies that are directed against anionic phospholipids or affiliated plasma proteins and are frequently associated with a prothrombotic state. 1 When associated with clinical manifestations, aPLA are an essential component of the diagnosis of the antiphospholipid syndrome (APS). 2 Still, aPLA are also found in healthy individuals or associated with infections without clinical manifestations of APS. [3] [4] [5] [6] So far, the pathogenesis of thrombotic manifestations in LA positive patients is not completely understood and the clinical impact of aPLA positivity is yet unclear. 7 The occurrence of arterial and venous thromboembolism (TE) not only causes acute, potentially fatal organ damage, but may also compromise long term organ functionality, possibly further aggravated by the association of aPLA positivity with autoimmune disorders, such as systemic lupus erythematodes (SLE) or other autoimmune diseases. 8 So far, most investigations on the morbidity and mortality of aPLA positive patients have focused on patients with SLE or patients already diagnosed with APS. In those cohorts, increased mortality has been reported for patients with APS. 9 Still, the clinical significance of LA positivity, associated with incidence and recurrence rates of TE and their impact on mortality have not been systematically analyzed as yet.
We conducted a prospective observational cohort study on persistently LA positive individuals with and without a prior history of thrombosis or pregnancy complications: the Vienna LATS (Lupus Anticoagulant and Thrombosis Study). The aim of our study was to investigate overall mortality of our cohort of LA patients and to evaluate the impact of thrombosis on survival during the observation period.
Patients and Methods
Starting from May 2001, adult patients that had repeatedly tested positive for LA within at least 6 or 12 weeks according to current recommendations 2,10,11 were consecutively included in this prospective study after having given written informed consent. All included patients were asked to perform follow up visits at the outpatient ward of our center every 6 months during the first 5 years, then at yearly intervals.
Data on previous and newly developed arterial and venous thromboembolic events, concomitant diseases and medication were collected using a standardized questionnaire and chart review. All registered events had to be symptomatic and diagnosed with standardized methods (duplex sonography or phlebography for venous thrombosis, computed tomography (CT) or ventilation-perfusion lung scan for pulmonary embolism, coronary arteriography for For personal use only. on December 29, 2017 . by guest www.bloodjournal.org From myocardial infarction, and CT or magnetic resonance imaging (MRI), CT/MRI angiography or transcranial duplex sonography for stroke, transient ischemic attacks were diagnosed on the basis of the typical clinical presentation). All events occurring during the follow-up period were separately evaluated and adjudicated.
A blood sample was drawn at inclusion and at every visit and the LA and aCL and anti-ß2GPI antibodies were determined. In case a patient became LA negative, he/she was excluded from further analysis. If the patient missed a scheduled visit, the questionnaire was completed by telephone interview or through chart review. Documented diagnoses of SLE, lupus like disease (LLD) or other autoimmune diseases were re-evaluated by a specialized rheumatologist according to the ACR criteria and recorded correspondingly. 12, 13 Causes of death were identified by review of death certificates, autopsy records or through personal contact with the family physician, hospitals or nursing homes. For comparison, data on the mortality of the Austrian general population was obtained from the Austrian death registry. 
Blood sampling and sample preparation
Blood samples were drawn with a 21-gauge butterfly needle (Greiner Bio-One, Kremsmuenster, Austria) into a Vacuette tube (Greiner Bio-One, Kremsmuenster, Austria) containing trisodium citrate (9 parts of whole blood, 1 of trisodium citrate 3.8 %). All samples were mixed adequately by gently inverting the tubes and were processed within three hours after venipuncture. Platelet-poor plasma was prepared by centrifugation at 2,500g for 15 minutes at 15°C, followed by a second step of centrifugation of the harvested plasma under the same conditions.
Determination of LA
Diagnosis of LA followed the SSC/ISTH recommendations. 11, 14 We used two different screening tests: a lupus-sensitive activated partial thromboplastin time (aPTT) and a diluted Russell's viper venom time (dRVVT). In patients under therapy with vitamin K antagonists (VKA) only the aPTT was used as screening assay. In the case of prolongation of one or both screening tests, samples were further analysed and confirmatory tests were performed, as described in detail by Wenzel et al. 15 When, during the observation period, the confirmatory test was not definitely positive, LA was still regarded as positive, when the Rosner index, calculated as 100 × (clotting times of the 1:1 mixture -normal plasma)/patient's plasma was higher than 15. 16 As confirmatory assays the StaClot LA (Diagnostica Stago, Asniere sur Seine, France) and the dRVVT-LA confirm (Life Diagnostics, Clarkston GA, USA) were used. between two or more groups were assessed with the log-rank test. The association between new onset of TE and mortality was visualized using landmark analysis 17 (with an a priori specified landmark at 3 years after baseline). In a sensitivity analysis we used different landmark time points, which did not alter our findings regarding TE and survival (not shown).
Univariable and multivariable Cox regression models were used to evaluate the influence of baseline parameters on overall survival. TE was modeled as a time-dependent variable. Two patients experienced TE and death at the same day. In these patients, we specified the occurrence of TE to have happened one day prior to death. In a sensitivity analysis, we excluded these two patients in order to assess, whether or not they exert a disproportionate For personal use only. on December 29, 2017. by guest www.bloodjournal.org From influence on the regression coefficient for TE on survival. Life-tables of the Austrian population according to calendar year, sex, and age from 1947 to 2012 were obtained from the webpages of the Austrian National Office for Statistics (http://www.statistik.at/web_de/statistiken/bevoelkerung/sterbetafeln/index.html) and the Human Mortality Project Database (http://www.mortality.org). The relative survival of our cohort in comparison to the age-, sex-, and calendar-year-matched Austrian general population was calculated according to the Ederer II method. 18 Two-sided P-values less than 0.05 were regarded as statistically significant.
Results

Patient characteristics
In total, 159 LA positive patients were included in the study, of whom 2 patients were excluded due to LA negativity and 6 patients did not return for follow-up visits despite Table 2 . Two patients died from a fatal MI, and 2 patients died shortly after cancer-associated pulmonary embolism (PE). These deaths were regarded as definitely associated with TE. We regarded death as possibly related to TE in further 6 patients. In 4 of them cardiac arrest was the documented cause of death (2 patients with known ischemic cardiomyopathy), and in further 2 patients sudden death had occurred.
No autopsies were performed in these patients. 
Predictors of survival
The rate of newly developed TE events, especially in the arterial vascular bed, was increased in patients who died during the observation period compared to the rate of newonset TE in survivors (Table 3 ).
In a landmark analysis, patients with TE at 3 years of follow-up had a 5-and 10-year survival of 84.0% (95%CI, 49.9-95.7) and 49.7% (95%CI, 24.5-70.6), which was worse compared to patients without newly developed TE with survival rates of 98.0% (95%CI, 92.0-99.5) and 91.7% (95%CI, 79.7-96.7), respectively. Data are shown in Figure 1 .
Results of univariable and multivariable analysis of predictors of survival are listed in Table 4 .
In univariable analysis of time-to-death, the occurrence of a TE event during follow-up, advanced age, hypertension, and diabetes at study entry, were significant predictors of an adverse survival prognosis. New onset of arterial or venous TE remained a strong adverse prognostic factor even after multivariable adjustment for age and hypertension (Hazard ratio (HR)=5.95). The separate analysis of arterial and venous thrombosis identified the occurrence of arterial events as the strongest predictor of adverse survival prognosis in our cohort (HR=10.6). Even after multivariable adjustment for age and hypertension this impact on survival prevailed (HR=5.7). To exclude a disproportionate influence of the 2 fatal MIs on the regression coefficients, the analysis was also performed after exclusion of these events (data not depicted in Table 4 ). New onset of arterial thrombosis was still a strong predictor of survival (HR=7.3, 95%CI,2.5-21.2, P<0.001), which also remained significant after adjustment for age and hypertension (HR=3.9, 95%CI,1.3-11.1, P=0.01). The occurrence of newly developed venous events did not emerge as significant prognostic factor for survival, although the HR was 2.8 in multivariable adjustment for age and hypertension. We did not observe an effect of either a prior history of thrombosis or pregnancy complications, or oral anticoagulant therapy at study inclusion, or the diagnosis of concomitant autoimmune rheumatic disease on mortality. Positivity for anti-ß2GPI IgG/IgM or aCL IgG/IgM antibodies or triple antibody positivity was not associated with survival after adjustment for age, occurrence of thrombosis and hypertension. Diabetes at baseline and elevation of anti-ß2GPI IgG were univariably but not multivariably associated with overall survival, which is likely due to positive confounding by age and hypertension. Importantly, patients with elevated anti-ß2GPI IgG were younger (t-test P<0.001) and had a lower presence of hypertension (chi-squared P=0.05) at baseline than patients with anti-ß2GPI IgG below the cut-off. Conversely, patients with diabetes were older (t-test P<0.001) and more likely to have hypertension (chi-squared P<0.001). 
Discussion
In our cohort of patients with persistent LA followed prospectively within the Vienna LATS we could demonstrate that the occurrence of thromboembolic events in these patients is 20 In that multicenter prospective cohort study the authors collected data of 1000 patients and followed them for 10 years, 419 were lost to follow up during the observation period. In contrast to our study they also included patients with antibodies against cardiolipin or β 2-GPI only. Similar to our data, in the Euro-Phospholipid project death was independent of anticoagulation, age and concomitant autoimmune disease, which is somewhat unexpected, as one would surmise that anticoagulation would protect patients from experiencing fatal thrombotic events.
Thromboembolic events definitely accounted for 20.0% of deaths in our population and 36.5% in the Euro-Phospholipid project. Most probably the thrombotic tendency is heterogeneous in patients with APS. In most APS patients who have experienced thrombosis, long-term anticoagulant therapy is initiated -however, this does not eliminate the risk of death, especially not in those experiencing new thrombotic events. It may well be that closely monitored anticoagulant treatment might prevent a new onset of TE and therefore counteract an even higher increase in mortality. The fact that mortality was not associated with the history of thrombosis but with new occurrence of thrombosis during the observation For personal use only. on December 29, 2017. by guest www.bloodjournal.org From period in our LA positive patients suggests that on the one hand anticoagulation appears effective, but that on the other hand, however, history of thromboembolism or other markers (such as positivity for other antiphospholipid antibodies) might not precisely identify patients at the highest risk of death. Death was also independent of concomitant ARD in our study as well as in the Euro-phospholipid cohort. 20 To compensate for a possibly deteriorating effect, patients with ARD could undergo more frequent controls at specialized clinics -this measure might help to prevent increased ARD-related mortality.
Particularly arterial thromboses, such as stroke and TIA, myocardial infarction and peripheral arterial thrombosis worsened survival in our cohort of LA positive patients with an up to 10fold increased risk of death. Interestingly, also the rates of non-thrombosis related death from hemorrhage (25%) or sepsis (15%) were surprisingly high in our cohort and in line with those reported by Cervera et al. 20 In that cohort 36.5% died of TE and a high rate of fatal infections (26.9%) was described. Thus, the reported increase in mortality cannot be solely interpreted as a consequence of fatal thrombotic events or the TE-associated deterioration of organ systems. Rather, our data indicate that more severe courses of disease might be associated with the occurrence of fatal or non-fatal arterial thrombosis during the observation period.
New onset of venous TE during the observation period was associated with a 3-fold increased risk of death. In studies in patients without APS and with primary manifestation of DVT, mortality after the acute phase was mainly increased due to cancer-associated deaths 21, 22 and survival was not impaired, if thrombotic manifestations triggered by cancer or aPLA positivity were excluded. [23] [24] [25] This has also been confirmed in patients with hereditary thrombophilia with and without thrombosis. In a follow up study of the European Prospective Cohort of Thrombophilia (EPCOT) no increased mortality in comparison to a control population was observed, not even in persons with thrombotic manifestations. 23 As clearly shown by our data and others 20 , patients with APS differ from these observations and have a considerably increased risk of long-term mortality.
The probability of survival in our cohort was 92% after 5 and 80% after 10 years and was inferior to that reported by Cervera et al (94% after 5 years and 91% after 10 years). 20 This difference might be due to the inclusion of LA positive patients only, as LA is thought to carry the highest risk for thrombosis among all antiphospholipid antibodies. 26, 27 Furthermore we also included patients without previous thrombotic manifestations and thus also without Seventy-seven percent of patients were receiving antithrombotic therapy at the time of the arterial or venous event. This leads to the conclusion that anticoagulant treatment might not sufficiently prevent thrombosis in LA positive individuals. [28] [29] [30] Treatment strategies for primary and secondary thromboprophylaxis in aPLA positive patients and patients with APS are still a matter of debate. [30] [31] [32] According to our data, thromboprophylaxis in LA positive individuals should be carefully evaluated to prevent thrombosis and increased mortality.
With our observational design we hardly can comment on the efficacy of anticoagulation to prevent recurrent thrombosis and death. Data that investigate the recurrence of VTE in patients with APS in interventional studies are scarce and do not allow firm conclusions with regard to the need for long term anticoagulation. [33] [34] [35] In a systematic review the risk ratio for recurrence in LA positive patients was 2.82, however, this was not statistically significantly different in comparison to those without (95%CI, 0.83-9.64), and important methodological limitations in most of the studies were noted. 36 Two trials compared high dose versus conventional intensity of treatment with VKA and did not find a difference of recurrence rates. 37, 38 Data from interventional studies are urgently required to evaluate other anticoagulant regimens for the prevention of thrombotic events in this particular patient group. 39 The choice of the anticoagulant needs to be carefully evaluated, as the occurrence of thrombosis and the associated deterioration in the survival prognosis do not seem to be sufficiently prevented by common treatment strategies. Clinical studies on the use of direct oral anticoagulants and/or immuno-suppressive or -modulatory therapeutics are currently conducted.
Our study has several limitations, one important is the relatively small number of patients.
However, adult patients with persisting LA are rare and our observation period was long.
With a median observation period of more than 8 years and 151 patients we covered in total more than 1000 patient years at risk of death. The inclusion of patients with the LA only, but not of those with only aCL or anti-β2GPI antibodies could also be interpreted as limitation.
However, LA is the strongest risk factor for thromboembolism 26 and the diagnosis of the presence of LA follows strict guidelines. For other antiphospholipid antibodies, specifically for anti-β2GPI antibodies the cut-off for diagnosis of APS is an elevation above normal. There For personal use only. on December 29, 2017. by guest www.bloodjournal.org From could be a bias in other studies, as still various assays lead to different results 14, 40 and false positive results cannot be excluded. We are convinced that the single center approach is a strength of our study, as only 11% of our LA positive patients were not followed until the defined end of observation.
We conclude from our data that patients with LA are at an increased risk of death, especially those with new onset or recurrence of arterial thrombotic manifestations. Whether this risk can be decreased by a more rigid regime of anticoagulation or anticoagulants other than vitamin K antagonists, still remains to be investigated. 
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* N1 represents the total number of patients, n1 the number of deaths in N1. N2 represents the number of patients with the respective characteristic, n2 the number of deaths in N2. †Multivariable analysis adjusted for age, hypertension and TE during FU (variables "TE during FU", "Hypertension at study inclusion" and "Age at study inclusion" are adjusted only for each other). ‡ Patients with at least one pregnancy (n=95). Pregnancy complications were defined according to the current criteria. 2,10 §Cut off: anti-ß2GPI >8 GPL/MPL U/mL, aCL >40 GPL/MPL U/mL. 
